Abstract
This chapter surveys the framework under which radiopharmaceuticals are used for the assessment of CSF flow and therapy of leptomeningeal metastasis (LM). The scientific basis is reviewed for development of radiopharmaceuticals for use in LM. The opportunities and limitations in choices of radiopharmaceuticals, imaging, and dosimetry schemes are discussed. Potential novel radiopharmaceuticals and novel use of existing radiopharmaceuticals are examined for future design of radiopharmaceutical trials in LM.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Becker B. Cerebrospinal fluid iodide. Am J Phys. 1961;201:1149–51.
Madsen JR, et al. Cerebrospinal fluid anion transport: studies of pertechnetate in unanesthetized sheep. Neurosurgery. 1985;17(5):778–83.
Coben LA, Smith KR. Iodide transfer at four cerebrospinal fluid sites in the dog: evidence for spinal iodide carrier transport. Exp Neurol. 1969;23(1):76–90.
Post RM, Allen FH, Ommaya AK. Cerebrospinal fluid flow and iodide 131 transport in the spinal subarachnoid space. Life Sci. 1974;14(10):1885–94.
Lashford LS, et al. A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer. 1988;61(5):857–68.
Bigner DD, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1–14 F (ab')2—a preliminary report. J Neurooncol. 1995;24(1):109–22.
Zhang X, et al. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020;117(5):2265–7.
Pandit-Taskar N, et al. Biodistribution and dosimetry of intraventricularly administered (124)I-omburtamab in patients with metastatic leptomeningeal tumors. J Nucl Med. 2019;60(12):1794–801.
Moseley RP, Papanastassiou V, Zalutsky MR. Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer. 1992;52(1):38–43.
Moseley RP, et al. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer. 1990;62(4):637–42.
Hesterman JY, et al. Three-dimensional dosimetry for radiation safety estimates from intrathecal administration. J Nucl Med. 2017;58(10):1672–8.
van Dieren EB, et al. A dosimetric model for intrathecal treatment with 131I and 67Ga. Int J Radiat Oncol Biol Phys. 1994;30(2):447–54.
Stabin MEJ. The radiation dosimetry of intrathecally administered radionuclides. In: Sixth international radiopharmaceutical dosimetry symposium. ORISE; 1999. 99-0164. p. 5–514.
Brown MT, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res. 1996;2(6):963–72.
Hicks RJ, et al. (64)Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. J Nucl Med. 2019;60(6):777–85.
Laffon E, de Clermont H, Marthan R. An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [(64/67)Cu]Cu-SARTATE. EJNMMI Res. 2021;11(1):75.
Acknowledgement
The author also thanks Dr. E. Edmund Kim of the University of California, Irvine for serving as collaborator on protocol DR10-0344 to evaluate patient studies while in M.D. Anderson Cancer Center.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Wong, F.C.L. (2022). Radionuclides in the Management of Leptomeningeal Metastasis: Framework and Opportunities. In: Wong, F.C. (eds) Radiopharmaceuticals in the Management of Leptomeningeal Metastasis. Springer, Cham. https://doi.org/10.1007/978-3-031-14291-8_12
Download citation
DOI: https://doi.org/10.1007/978-3-031-14291-8_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14290-1
Online ISBN: 978-3-031-14291-8
eBook Packages: MedicineMedicine (R0)